Please assess the completion status of the following clinical trial:

Trial Title: A Safety Study of Eptifibatide in Patients With Sickle Cell Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age between 18 and 55 years~2. Have confirmed diagnosis of sickle cell anemia or sickle beta zero thalassemia~3. Have a serum creatinine \</= 1.2 mg/dl~4. Have serum transaminase values \< 3 times upper limits of normal~5. Have a platelet count \>/= 150 x 10\^9/L~6. Have normal baseline coagulation profile~7. Sudden onset of pain involving one or more sites and typical of usual pain episodes~8. Have adequate intravenous access~9. Be able to understand the requirements of the study and be willing to give informed consent~10. Women of child-bearing age must be practicing (and will continue to practice for the course of the study) an adequate method of contraception (oral contraception, depo-provera, bilateral tubal ligation or barrier method)~Exclusion Criteria:~1. Have a baseline hemoglobin \< 6.0 gm/dl~2. Have a history of major gastrointestinal bleeding or a bleeding diathesis~3. Have an ongoing episode of acute chest syndrome~4. Have a past history of clinically overt stroke(s)~5. Have severe hypertension (systolic blood pressure \> 200mmHg and/or diastolic BP \>110mmHg) not adequately controlled on hypertensive medication~6. Have had major surgery within the six weeks preceding enrollment~7. Are pregnant or breastfeeding~8. Are on chronic anticoagulation or antiplatelet (including non-steroidal anti-inflammatory drugs) therapy~9. Have a history of metastatic cancer~10. Are on a chronic transfusion program or have received a blood transfusion in the prior 8 weeks~11. Have a positive urine toxicology screen for phencyclidine, cocaine or amphetamines.~12. Have a history of alcohol abuse~13. Have received any investigational drugs within the past 4 weeks.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): As soon as eligible patients are identified and provide consent to participate in the study, patients randomized to the eptifibatide arm will receive two 180 mcg/kg boluses of eptifibatide 10 minutes apart (i.e., a double bolus), followed by a continuous infusion at 2 mcg/kg/min for 6 hours.
- 2 (Type: PLACEBO_COMPARATOR): As soon as eligible patients are identified and provide consent to participate in the study, patients randomized to the placebo arm will receive a saline solution delivered at a volume and rate identical to that of the active drug.

Based on this trial design, predict the completion outcome and termination type (if applicable).